NASDAQ:DXCM - DexCom Stock Price, Forecast & News

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings results on Thursday, February, 13th. The medical device company reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.41. The medical device company earned $462.80 million during the quarter, compared to analysts' expectations of $457 million. DexCom had a return on equity of 22.65% and a net margin of 6.85%. View DexCom's Earnings History.

DexCom is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for DexCom.

DexCom issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.725-1.775 billion, compared to the consensus revenue estimate of $1.77 billion.

18 Wall Street analysts have issued twelve-month target prices for DexCom's stock. Their forecasts range from $125.00 to $300.00. On average, they anticipate DexCom's stock price to reach $259.22 in the next twelve months. This suggests that the stock has a possible downside of 11.8%. View Analyst Price Targets for DexCom.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DexCom.

Media headlines about DXCM stock have trended neutral recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. DexCom earned a news sentiment score of 0.4 on InfoTrie's scale. They also gave press coverage about the medical device company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for DexCom.

DexCom saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 4,750,000 shares, a drop of 5.4% from the January 15th total of 5,020,000 shares. Based on an average trading volume of 986,900 shares, the days-to-cover ratio is presently 4.8 days. Currently, 5.3% of the company's stock are sold short. View DexCom's Current Options Chain.

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX), Varian Medical Systems (VAR) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), salesforce.com (CRM), Netflix (NFLX), Micron Technology (MU), Mastercard (MA), ServiceNow (NOW), Adobe (ADBE) and Advanced Micro Devices (AMD).

DexCom's stock is owned by a number of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (5.26%), Jennison Associates LLC (3.78%), Capital World Investors (3.50%), Artisan Partners Limited Partnership (2.06%), Blair William & Co. IL (1.32%) and Geode Capital Management LLC (1.22%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Jennison Associates LLC, Victory Capital Management Inc., Victory Capital Management Inc., Janus Henderson Group PLC, Peregrine Capital Management LLC, Columbus Circle Investors and First Trust Advisors LP. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Steven R Altman and Steven Robert Pacelli. View Insider Buying and Selling for DexCom.

DXCM stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Fred Alger Management LLC, Beacon Investment Advisory Services Inc., Baird Financial Group Inc., National Pension Service, Lord Abbett & CO. LLC, Kornitzer Capital Management Inc. KS and Cubist Systematic Strategies LLC. View Insider Buying and Selling for DexCom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $294.05.

DexCom has a market capitalization of $26.93 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe.View Additional Information About DexCom.

The official website for DexCom is http://www.dexcom.com/.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]